DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours
1997

Enzyme Levels in Lung and Breast Tumors

Sample size: 39 publication Evidence: moderate

Author Information

Author(s): A Marinn, A López de Cerain, E Hamilton, AD Lewis, JM Martinez-Peñuela, MA Idoate, J Bello

Primary Institution: Universidad de Navarra

Hypothesis

The levels of reductase enzymes in tumors can influence the effectiveness of bioreductive drugs.

Conclusion

The study found significant variability in the levels of DT-diaphorase in lung and breast tumors compared to normal tissues, suggesting the need for individualized assessment before therapy.

Supporting Evidence

  • In 53% of lung tumor samples, DTD activity was increased compared to normal tissue.
  • In 70% of breast tumor samples, DTD activity was over 80 nmol min-1 mg-1.
  • The study found significant differences in DTD activity based on tumor grade and stage.

Takeaway

This study looked at how certain enzymes in lung and breast tumors can help or hurt cancer treatments, showing that some tumors have much more of these enzymes than normal tissue.

Methodology

The study measured enzyme levels in paired tumor and normal tissue samples from patients using spectrophotometric assays and Western blot analysis.

Potential Biases

Potential bias due to the selection of patients and the variability in tumor types and treatments.

Limitations

The study had a small sample size and did not account for all potential confounding factors affecting enzyme levels.

Participant Demographics

The mean age of lung tumor patients was 65 years, predominantly smokers or ex-smokers; breast tumor patients were all females with a mean age of 51 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication